Chemours hit by securities fraud probe after 18.6% stock plunge

Glancy Prongay Wolke & Rotter LLP opened a securities fraud investigation into Chemours after shares fell 18.63% to $14.59 on August 5.

Chemours management said on the earnings call that "[a]s a result of the initial channel fill, aftermarket customers built additional inventory, creating an oversupplied channel heading into 2026." Management further disclosed that roughly $65 million of aftermarket sales "probably should have been allocated to more of this year."

The company cut its full-year adjusted EBITDA guidance to $775 million to $825 million, from $800 million to $900 million previously. Chemours reported Q2 revenue of $1.59 billion, up 15.21 percent from the prior quarter, and a net loss of $274 million, with EPS of negative $1.81. Net income decreased 548.84 percent year-over-year, while EPS fell 548.63 percent. The company's trailing twelve-month net income stands at negative $386 million on revenue of $5.81 billion, with EPS of negative $2.57.

The investigation adds legal and reputational risk to a company already under pressure. Chemours shares trade near the bottom of their 52-week range with a market capitalization of $2.29 billion, and the stock remains below its 200-day simple moving average. Shares opened at $14.96 on the most recent session, down $0.03 from the prior close.

The Wilmington, Delaware-based chemicals maker, founded in February 2014, operates through segments including Titanium Technologies, Thermal and Specialized Solutions, and Advanced Performance Materials. Its products serve coatings, plastics, refrigeration and air conditioning, transportation, semiconductors, and consumer electronics markets. The Titanium Technologies segment manufactures titanium dioxide pigment, while Thermal and Specialized Solutions produces refrigerants, propellants, and specialty solvents.

The channel oversupply issue stems from the initial distribution fill that pushed aftermarket inventory ahead of actual demand, a problem management acknowledged on the call. The guidance reduction reflects the expectation that excess inventory will take time to work through the system, weighing on near-term sales volumes across the aftermarket business.

The law firm is urging investors who lost money on Chemours stock to contact them about potentially pursuing claims. The SEC Whistleblower Program offers rewards of up to 30 percent of successful recoveries for individuals with non-public information about the company. Glancy Prongay Wolke & Rotter has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services, with nearly 40 attorneys across four offices.

The investigation could result in significant legal costs, potential settlement payouts, and increased regulatory scrutiny for Chemours. Investors will watch for any formal complaint filing and the company's response, with the next earnings report expected in the coming months.

This article is for informational purposes only and does not constitute investment advice.